Welcome to our dedicated page for Bowen Acqsn SEC filings (Ticker: BOWNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Bowen Acquisition Corp (BOWNR-related securities) provide detailed insight into how this Cayman Islands exempted SPAC structures its business combination process, trust account, shareholder rights and listing status. As a blank check company formed to complete a merger or similar business combination with one or more businesses, Bowen Acquisition Corp relies on formal SEC disclosures to outline its obligations to public shareholders and to describe its proposed transactions.
Key filings include registration statements and prospectus materials related to the initial public offering of units, which consisted of ordinary shares and rights. These documents explain the terms of the rights represented by BOWNR, including that each right entitles the holder to receive one-tenth of one ordinary share upon completion of an initial business combination, subject to adjustment. They also describe the establishment of a trust account funded with IPO and private placement proceeds, and the conditions under which public shareholders may redeem their shares for a pro rata portion of the trust account.
Bowen Acquisition Corp’s merger-related filings are central for understanding its proposed combination with Shenzhen Qianzhi BioTechnology Co. Ltd. and related entities. The company has indicated that it will file a registration statement on Form F-4 containing a proxy statement/prospectus describing the business combination, the structure of the merger between its wholly owned subsidiary and the Cayman Islands holding company parent of Qianzhi BioTech, the share consideration to be issued, and the potential earnout shares. These filings also provide information about Qianzhi BioTech’s business, which focuses on ozonated health and wellness products, and the expected governance of the combined company.
The definitive proxy statement (DEF 14A) filed on November 24, 2025, offers additional detail on corporate actions tied to the SPAC timeline. It describes an extraordinary general meeting to vote on an extension proposal that would allow the board of directors to extend the deadline to complete a business combination by up to six one-month increments beyond the current termination date. The proxy explains the mechanics of the extension, the redemption rights available to public shareholders who elect to redeem their public shares in connection with the extension, and the consequences if the extension is not approved, including winding up, redemption of public shares from the trust account, and liquidation.
Filings also address potential outcomes if a business combination is not completed. Bowen Acquisition Corp discloses that, absent an approved extension and a completed transaction by the termination date, it would cease operations except for winding up, redeem the public shares from the trust account, and proceed to liquidate and dissolve, with the rights expiring worthless and receiving no liquidation distribution. This framework is laid out in the company’s charter documents and described in detail in its proxy materials.
In addition, Bowen Acquisition Corp’s public communications reference Nasdaq-related filings, including the potential filing of a Form 25-NSE by Nasdaq to remove the company’s securities from listing and registration on the Nasdaq Stock Market if a delisting determination is not successfully appealed. While such forms are initiated by the exchange, they are part of the broader regulatory record affecting BOWNR-linked securities.
On Stock Titan’s SEC filings page, users can review Bowen Acquisition Corp’s 10-K and 10-Q reports, proxy statements, registration statements and any Form 8-K current reports related to the proposed business combination, extensions, or listing developments. AI-powered summaries can help explain complex sections, such as trust account provisions, redemption mechanics, and the detailed terms of the merger with Shenzhen Qianzhi BioTech. The platform also highlights real-time updates from EDGAR, making it easier to track new filings as Bowen Acquisition Corp advances its business combination process or responds to Nasdaq listing actions.
Bowen Acquisition Corp (BOWN) is calling an extraordinary general meeting on December 12, 2025 for shareholders to vote on extending the deadline to complete its initial business combination. The Extension Proposal would allow the board to push the current termination date from December 14, 2025 by up to six one‑month increments, to as late as June 14, 2026. A separate Adjournment Proposal would let the board adjourn the meeting if more time is needed to secure approval.
Bowen has a signed deal with Shenzhen Qianzhi BioTechnology Co. Ltd., which shareholders approved in January 2025 but has not yet closed. Public shareholders may elect to redeem their shares for cash; based on about $8.26 million in the trust as of November 20, 2025, the company estimates a redemption price of roughly $11.35 per share. If the Extension Proposal fails and no deal closes by December 14, 2025, Bowen would redeem all public shares and liquidate. Shareholders who do not redeem now, and did not redeem at the earlier Qianzhi vote, will not have redemption rights when that business combination is completed.